All News

Patients with sickle cell disease with more than a 6-month delay transitioning from pediatric to adult care were about twice as likely to be hospitalized.

Promises of sexual improvement may ensnare unsuspecting patients with potentially dangerous adverse effects from untested OTC remedies.

Data analysis can help hospitals address waste of controlled substances that fuels diversion and increased costs.

Data presented at ASCO 2024 show fam-trastuzumab deruxtecan-nxki (T-DXd) delayed cancer growth in patients with hormone receptor-positive (HR+), HER2-low or -ultralow disease that progressed following endocrine therapy (ET).

The phase 3 LAURA trial data presented at ASCO 2024 showed osimertinib (Tagrisso; AstraZeneca) reduced risk of disease progression or death in patients with stage 3 EGFR-mutated (EGFRm) non–small cell lung cancer (NSCLC) by 84%.

Results from the trial provide evidence bolstering ASCO’s clinical practice guideline supporting the integration of early palliative care into standard oncology practice.

Matthew A. Gubens, MD, MS, FASCO, highlights the importance of identifying genetic targets in metastatic non–small cell lung cancer (NSCLC), emphasizing the latest updates and strategies.

Understanding patients’ specific experiences and challenges is crucial to helping them improve medication adherence.

The addition of ribociclib (Kisqali; Novartis) to endocrine therapy demonstrated a 28% risk reduction in invasive disease-free survival.

In addition to medication management, pharmacists are educating patients and helping them navigate the complex medical system.

The priority review of inavolisib is for treatment of patients with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

Although this data seems to overwhelmingly suggest that cannabis use has negative impacts for individuals with multiple sclerosis (MS), listening to patients’ reasoning for using it is crucial.

Women who received epidural analgesia during labor were less likely to experience severe maternal morbidity complications, such as heart attack or heart failure and sepsis.

This is Moderna's second mRNA vaccine approval and the first mRNA vaccine approved for an indication other than COVID-19.

Quadruple therapies including immunotherapy agents show promise in treating patients with multiple myeloma.

Subcutaneous ocrelizumab can be delivered in approximately 10 minutes and deliver comparable clinical benefit and safety to the IV formulation.

The study compares the safety and efficacy of mRNA-1345 compared to placebo.

Pediatric patients with rheumatic disease, such as systemic lupus erythematosus, mixed connective tissue disease, juvenile dermatomyositis, and systemic vasculitis are at an increased risk of serious infection.

Study investigators hired undercover shoppers, and the results revealed more education is needed on the Syringe Service Program, which provides legal, clean over-the-counter (OTC) needles to whomever seeks them out.

Topline results of QWINT-2 and QWINT-4 met the primary end point of change in hemoglobin A1c compared to degludec and glargine, respectively, for those with type 2 diabetes.

A review of asthma guidelines, pharmacotherapy, and the role of the pharmacist.

Tools provide a safer testing option without using the viral proteins that cause infection.

Lisocabtagene maraleucel (Breyanzi; Bristol Myers Squibb) is a CD19-directed CAR T-cell therapy that is delivered as a one-time infusion.

Although resources were scarce for teams at smaller private practices, the pharmacists all agreed that patient care is always the priority.

Individuals from a lower socioeconomic group showed more benefits from low-dose CT screening relating to lung cancer survival.

There has been a general shift toward earlier treatment and less tolerance for clinically silent disease activity.

The treatment is indicated for adult patients with tardive dyskinesia and Huntington disease chorea, with tablets now available in 4 different doses.